Olivia Esposito • June 2, 2023
The University of Maryland – Baltimore, MD

The Hypertrophic Cardiomyopathy Program at the University of Maryland Heart & Vascular Center is Recognized as an HCMA Center of Excellence and the only HCMA-recognized center in the state of Maryland at this time. The University of Maryland’s team of cardiologists, cardiac surgeons, geneticists, electrophysiologists, nutritionists, and physical therapists are ready to treat you and guide you toward healthy lifestyle choices as you learn to live with this disease. An accurate diagnosis is the first step to treatment. Once we have confirmed your specific condition, The University of Maryland Team can begin tailoring your care plan. The team is currently seeing patients in Baltimore, Columbia, Owings Mills, and Westminster.

The University of Maryland team consists of the following members:

  • Libin Wang, MD, PhD- Program Director
  • Vincent See, MD- Co-Director
  • Carissa Baker-Smith, MD, MS, MPH- Pediatric Transplant
  • Timm Dickfeld, MD, PhD- Electrophysiology
  • Erika Feller, MD- Heart Transplant
  • Stacy Fisher, MD- Adult Congenital
  • James Gammie, MD- Surgery
  • Carol Greene, MD- Genetics
  • Susie Hong-Zohlman, MD, MSc- Cardiac Imaging
  • Geoffrey Rosenthal, MD, PhD- Pediatric Cardiology
  • Sudhir Vashist, MD- Pediatric Electrophysiology
  • Mark Vesely, MD- Interventional Cardiology
  • Charles White, MD- Radiology/MRI

Please join the HCMA as we feature The University of Maryland HCM team for our next virtual stop of the Bighearted Warriors Unite tour on June 15th at 6:30 PM EST. Highlights are as follows:  Taking care of children with HCM, One year with Mavacamten, Improving the care of atrial fibrillation in HCM & Gene therapy for HCM. Register here for this free event: https://4hcm.org/inspire_events/bighearted-warriors-unite-featuring-university-of-maryland/

Please visit for more information about The University of Maryland –  Heart & Vascular Center in Baltimore, MD please visit: https://4hcm.org/maryland/  


For more information on all HCMA Recognized Centers of Excellence, please visit https://4hcm.org/center-of-excellence/.

Stacey Titus, Center of Excellence Coordinator

For more information on all HCMA Recognized Centers of Excellence, please visit  https://4hcm.org/center-of-excellence/.

HCMA Blog

March 24, 2025
Who should have genetic testing, and when?
A photo-realistic image of  heart, lit from behind, on a black background.
March 11, 2025
Health educator Sabrina Cuddy discusses common arrhythmias in HCM, like atrial flutter/fibrillation, ventricular tachycardia/fibrillation, left or right bundle branch block, PVC, PAC, and others. Some arrhythmias are harmless, while others are serious and need treatment.
Chart representing mavacamten trial results with total patients, and results in blue bar format.
By Gordon Fox March 10, 2025
Camzyos provided significant reduction of obstruction. Initially all patients were obstructed (that is, they had gradients of at least 30mmHg after valsalva maneuvers). After 3 months on Camzyos, about 57% were no longer obstructed. After 6 months, about 70% had no obstruction.
More Posts
Share by: